These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9878019)

  • 1. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
    Romano L; Venturi G; Catucci M; De Milito A; Valensin PE; Zazzi M
    J Infect Dis; 1999 Feb; 179(2):361-6. PubMed ID: 9878019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
    J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
    J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy.
    Zhang J; Crumpacker CS
    J Infect Dis; 2001 Nov; 184(10):1341-4. PubMed ID: 11679927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
    J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy.
    Venturi G; Romano L; Carli T; Corsi P; Pippi L; Valensin PE; Zazzi M
    Antivir Ther; 2002 Dec; 7(4):245-50. PubMed ID: 12553478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy.
    Saladini F; Vicenti I; Razzolini F; Zazzi M
    Clin Microbiol Infect; 2010 Jul; 16(7):848-51. PubMed ID: 19681953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy.
    Vitone F; Gibellini D; Schiavone P; Re MC
    J Clin Virol; 2005 Jul; 33(3):194-200. PubMed ID: 15911440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons.
    Blackard JT; Smeaton L; Hiasa Y; Horiike N; Onji M; Jamieson DJ; Rodriguez I; Mayer KH; Chung RT
    J Infect Dis; 2005 Jul; 192(2):258-65. PubMed ID: 15962220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
    Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri AC; Phillips AN
    J Infect Dis; 1999 Aug; 180(2):530-3. PubMed ID: 10395876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood mononuclear cells of HIV- and HCV-antibody-positive individuals contain HCV RNA but No HCV DNA despite evidence for reverse transcription of HIV RNA into DNA.
    Penning M; Beld M; Goudsmit J
    Virology; 2000 Mar; 268(1):12-6. PubMed ID: 10683322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of HIV-1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T-cell count.
    Kupfer B; Kaiser R; Rockstroh JK; Matz B; Schneweis KE
    J Med Virol; 1998 Nov; 56(3):259-63. PubMed ID: 9783695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
    Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL
    J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
    Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
    J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.